BRTX

$0.25

Post-MarketAs of Mar 17, 8:00 PM UTC

BioRestorative Therapies, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$0.25
Potential Upside
5%
Whystock Fair Value$0.26
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The c...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.45M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.41
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-207.73%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.31

Recent News

Zacks
Mar 17, 2026

Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -17.02% and -72.90%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Associated Press Finance
Mar 10, 2026

BC-Most Active Stocks

Elong Power Holding Ltd. 356,032,309 0.0734

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Nov 13, 2025

BioRestorative (BRTX) Earnings Call Transcript

Need a quote from a Motley Fool analyst? On behalf of the management team and everyone at BioRestorative Therapies, I would like to thank you for your interest in our company. With that said, I'd like to ask Robert Eugene Kristal, our CFO, to provide a brief overview of our third-quarter financial results.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Nov 13, 2025

BioRestorative Therapies Inc (BRTX) Q3 2025 Earnings Call Highlights: Strategic Advancements ...

BioRestorative Therapies Inc (BRTX) secures FDA fast track for BRTX 100, strengthens commercial infrastructure, but faces revenue decline and increased net loss.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Nov 12, 2025

Biorestorative Therapies, Inc. (BRTX) Reports Q3 Loss, Lags Revenue Estimates

Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of 0.00% and -97.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.